Tygacil Hospital Antibiotic Launch Expected Within 12 Months
This article was originally published in The Pink Sheet Daily
Wyeth hopes to launch the injectable antibiotic Tygacil (tigecycline) within the next 12 months, CEO Robert Essner told the Bear Stearns conference in New York Sept. 14.
You may also be interested in...
The first-in-class glycylcycline antibiotic could be a monotherapy option in the treatment of complicated infections, Wyeth says. The company would likely detail the injectable alongside its antibiotic Zosyn.
US FDA’s Accelerated Approval process has always been a deceptively simple idea. After a three-day public review of ‘dangling’ applications, the underlying complexity remains.